(Q79290519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Prognostic Significance of Serum Soluble Fas Level and Its Change during Regression and Progression of Advanced Prostate Cancer (English)

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

1 April 2024

1 reference

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

1 April 2024

author name string

Yuzo Furuya

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Osamu Nagakawa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Hideki Fuse

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14614220

1 April 2024

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

629-633

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14614220%20AND%20SRC:MED&resulttype=core&format=json

Fas and Fas ligand: a death factor and its receptor.

21 December 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity

1 April 2024

2

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Fas-mediated cytotoxicity by freshly isolated natural killer cells

1 April 2024

3

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

1 April 2024

6

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Serum soluble Fas levels in ovarian cancer

1 April 2024

7

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Prognostic significance of soluble Fas in the serum of patients with bladder cancer

1 April 2024

9

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Soluble Fas in serum from patients with renal cell carcinoma

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma

1 April 2024

12

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Expression of the functional soluble form of human fas ligand in activated lymphocytes.

1 April 2024

14

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Circulating soluble Fas ligand in patients with gastric carcinoma

1 April 2024

15

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Elevated serum soluble Fas ligand in natural killer cell proliferative disorders

1 April 2024

16

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?

1 April 2024

17

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 April 2024

19

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity

1 April 2024

20

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Immunohistochemical study of Fas, Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer.

1 April 2024

21

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629

Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo

1 April 2024

22

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.629